AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-04-19 pm EDT 5-day change 1st Jan Change
166.4 USD +1.06% Intraday chart for AbbVie Inc. +2.93% +7.38%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Advance Late Afternoon MT
Sector Update: Health Care Stocks Rise Friday Afternoon MT
Sector Update: Health Care MT
Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US MT
Deutsche Bank Raises AbbVie's Price Target to $175 Form $170 MT
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US MT
Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix... Our Logo
AbbVie Says Potential Treatment for Giant Cell Arteritis Met Endpoints in Phase 3 Study MT
AbbVie Study on Treatment for Giant Cell Arteritis Meets Primary Endpoint DJ
AbbVie Announces Positive Top-Line Results from SELECT-GCA Study of Upadacitinib Showed Positive Results in Patients with Giant Cell Arteritis CI
OSE: licensing agreement with AbbVie enters into force CF
OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie MT
Medincell: share price rises following agreement with AbbVie CF
Medincell, AbbVie to Co-Develop Injectable Therapeutics DJ
AbbVie Says Phase 3 Interim Data Support Long-Term Efficacy, Safety of Migraine Drug MT
AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine CI
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease RE
Boehringer to lay off salespeople as Humira biosimilar sales lag RE
Boehringer to lay off salespeople as Humira biosimilar sales lag RE
AbbVie Flags Hit to Q1 Adjusted Earnings from R&D Expenses, Revises 2024 Outlook MT
US takes next step in Medicare drug price negotiations with pharma companies RE
Roivant's anti-inflammatory drug succeeds in mid-stage study RE
Barclays Raises AbbVie Price Target to $195 From $185, Maintains Overweight Rating MT
Deals of the day-Mergers and acquisitions RE
Sector Update: Health Care Stocks Decline Late Afternoon MT
Chart AbbVie Inc.
More charts
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
164.7 USD
Average target price
184.1 USD
Spread / Average Target
+11.83%
Consensus
  1. Stock Market
  2. Equities
  3. ABBV Stock
  4. News AbbVie Inc.
  5. AbbVie Secures Rights to OSE Immunotherapeutics' Drug Candidate